Table 2.
Subjects number | Drug | Cycle(s) | Interval between PET/CT month(s)* | SUVmax of thyroid | TBR |
---|---|---|---|---|---|
2 | Rituximab | 4 | 2 | 3 | 4.9 |
9 | Navuliumab | 3 | 1 | 4.2 | 7.64 |
17 | Carrelizumab | 1 | 1 | 6.1 | 7.46 |
The interval between PET/CT examination and the end of the previous cycle of treatment.